| 116.99 -0.17 (-0.15%) | 09-10 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 141.23 | 1-year : | 164.96 |
| Resists | First : | 120.91 | Second : | 141.23 |
| Pivot price | 118.43  |
|||
| Supports | First : | 113.23 | Second : | 108.48 |
| MAs | MA(5) : | 117.33  |
MA(20) : | 117.32 |
| MA(100) : | 107.31 |
MA(250) : | 102.49 |
|
| MACD | MACD : | 1.5 |
Signal : | 2 |
| %K %D | K(14,3) : | 31.4 |
D(3) : | 41.6 |
| RSI | RSI(14): 54.6 |
|||
| 52-week | High : | 120.91 | Low : | 92.19 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ NVS ] has closed above bottom band by 24.2%. Bollinger Bands are 20% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 117.26 - 117.87 | 117.87 - 118.4 |
| Low: | 114.58 - 115.29 | 115.29 - 115.89 |
| Close: | 115.82 - 117.03 | 117.03 - 118.05 |
Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company operates through two segments, Innovative Medicines and Sandoz. The Innovative Medicines segment offers prescription medicines for patients and healthcare providers. It also provides ophthalmology, neuroscience, immunology, hepatology, dermatology, respiratory, cardiovascular, renal, and metabolism medicine products. The Sandoz segment develops, manufactures, and markets finished dosage form medicines; active ingredients and finished dosage forms of small molecule pharmaceuticals to third parties; and retail generics and anti-infectives. It also provides active pharmaceutical ingredients and intermediates primarily antibiotics; protein- or other biotechnology-based products, including biosimilars; and biotechnology manufacturing services. Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran; and a clinical collaboration with Kura Oncology, Inc. to evaluate the combination of Tipifarnib and Alpelisib in patients with head and neck squamous cell carcinoma. The company was incorporated in 1996 and is headquartered in Basel, Switzerland.
Mon, 09 Sep 2024
Novartis AG (NYSE:NVS) Receives $118.38 Consensus Price Target from Brokerages - MarketBeat
Sun, 08 Sep 2024
National Bank of Canada FI Grows Stake in Novartis AG (NYSE:NVS) - MarketBeat
Sat, 07 Sep 2024
Oxbow Advisors LLC Buys Shares of 25,547 Novartis AG (NYSE:NVS) - MarketBeat
Fri, 06 Sep 2024
Novartis to License VYGR's Capsid for Gene Therapy in Neurology - Yahoo Finance
Thu, 05 Sep 2024
Jim Cramer Says It Will Take Time For Novartis AG (NVS) To ‘Get The Attention Of Investors’ - Yahoo Finance
Wed, 04 Sep 2024
Novartis expands U.S. radiopharma production (NYSE:NVS) - Seeking Alpha
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NYSE
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Drug Manufacturers - General
|
|
| Shares Out | 2,020 (M) |
| Shares Float | 1,930 (M) |
| Held by Insiders | 0 (%) |
| Held by Institutions | 6.9 (%) |
| Shares Short | 5,870 (K) |
| Shares Short P.Month | 6,230 (K) |
| EPS | 4.88 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 20.61 |
| Profit Margin | 33.1 % |
| Operating Margin | 33.4 % |
| Return on Assets (ttm) | 8.8 % |
| Return on Equity (ttm) | 21.5 % |
| Qtrly Rev. Growth | 9.6 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 24.18 |
| EBITDA (p.s.) | 9.55 |
| Qtrly Earnings Growth | 43 % |
| Operating Cash Flow | 15,060 (M) |
| Levered Free Cash Flow | 14,810 (M) |
| PE Ratio | 23.97 |
| PEG Ratio | 2.1 |
| Price to Book value | 5.67 |
| Price to Sales | 4.83 |
| Price to Cash Flow | 15.69 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|